blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3151837

EP3151837 - PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.01.2024
Database last updated on 30.07.2024
FormerThe patent has been granted
Status updated on  10.02.2023
FormerGrant of patent is intended
Status updated on  20.10.2022
FormerExamination is in progress
Status updated on  02.12.2019
FormerRequest for examination was made
Status updated on  10.03.2017
FormerThe international publication has been made
Status updated on  21.12.2016
Most recent event   Tooltip10.05.2024Lapse of the patent in a contracting state
New state(s): BE, CH		published on 12.06.2024  [2024/24]
Applicant(s)For all designated states
Signpath Pharma, Inc.
9710 Ruskin Circle
Sandy, UT 84092 / US
For all designated states
Avanti Polar Lipids, LLC
700 Industrial Park Drive
Alabaster, Alabama 35007 / US
[2023/11]
Former [2022/48]For all designated states
Signpath Pharma, Inc.
1375 California Road
Quakertown, PA 18951 / US
For all designated states
Avanti Polar Lipids, LLC
700 Industrial Park Drive
Alabaster, Alabama 35007 / US
Former [2017/15]For all designated states
Signpath Pharma Inc.
1375 California Road
Quakertown, PA 18951 / US
For all designated states
Avanti Polar Lipids Inc.
700 Industrial Park Drive
Alabaster, Alabama 35007 / US
Inventor(s)01 / HELSON, Lawrence
1375 California Road
Quakertown, PA 18951 / US
02 / SHOPP, George, M.
860 Willowbrook Road
Boulder, CO 80302 / US
03 / BOUCHARD, Annie
16 Rue de la Pommeraie
Stoke, QC J0B 3G0 / CA
04 / MAJEED, Muhammed
20 Lake Drive
East Windsor, NJ 08520 / US
05 / BURGESS, Stephen
150 Twelve Oaks Circle
Chelsea, AL 35043 / US
06 / SHAW, Walter, A.
4621 Dolly Ridge Road
Birmingham, AL 35243 / US
 [2017/15]
Representative(s)SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
[N/P]
Former [2023/11]SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
Former [2017/15]Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
Application number, filing date15803421.503.06.2015
[2017/15]
WO2015US34078
Priority number, dateUS201462007244P03.06.2014         Original published format: US 201462007244 P
US201462035417P09.08.2014         Original published format: US 201462035417 P
US201462056957P29.09.2014         Original published format: US 201462056957 P
US201562150059P20.04.2015         Original published format: US 201562150059 P
[2017/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015187883
Date:10.12.2015
Language:EN
[2015/49]
Type: A1 Application with search report 
No.:EP3151837
Date:12.04.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 10.12.2015 takes the place of the publication of the European patent application.
[2017/15]
Type: B1 Patent specification 
No.:EP3151837
Date:15.03.2023
Language:EN
[2023/11]
Search report(s)International search report - published on:KR10.12.2015
(Supplementary) European search report - dispatched on:EP10.11.2017
ClassificationIPC:A61K31/685, A61K31/683, A61K31/661, A61K31/135, A61P9/00, A61K9/127, A61P9/06
[2017/50]
CPC:
A61K31/683 (EP,US); A61K45/06 (US); A61K31/20 (EP,US);
A61K31/23 (EP,US); A61K31/506 (US); A61K31/685 (EP,US);
A61K9/127 (EP,US); A61P9/00 (EP); A61P9/06 (EP);
G01N33/5008 (EP,US); G01N33/6872 (US); G01N33/6887 (EP,US);
G01N2800/32 (EP,US) (-)
C-Set:
A61K31/20, A61K2300/00 (US,EP);
A61K31/23, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (EP,US);
A61K31/683, A61K2300/00 (US,EP);
A61K31/685, A61K2300/00 (EP,US)
(-)
Former IPC [2017/15]A61K31/685, A61K31/661, A61K31/135, A61P9/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/15]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:SCHUTZWIRKUNG VON DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG UND LYSOPC GEGEN ARZNEIMITTEL, DIE KANALOPATHIEN HERVORRUFEN[2017/15]
English:PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES[2017/15]
French:EFFET PROTECTEUR DE DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG ET LYSOPC CONTRE DES MÉDICAMENTS PROVOQUANT DES CANALOPATHIES[2017/15]
Entry into regional phase21.12.2016National basic fee paid 
21.12.2016Search fee paid 
21.12.2016Designation fee(s) paid 
21.12.2016Examination fee paid 
Examination procedure21.12.2016Examination requested  [2017/15]
21.12.2016Date on which the examining division has become responsible
28.05.2018Amendment by applicant (claims and/or description)
05.12.2019Despatch of a communication from the examining division (Time limit: M04)
07.04.2020Reply to a communication from the examining division
30.09.2020Despatch of a communication from the examining division (Time limit: M04)
29.01.2021Reply to a communication from the examining division
29.03.2021Despatch of a communication from the examining division (Time limit: M04)
26.07.2021Reply to a communication from the examining division
21.10.2022Communication of intention to grant the patent
01.02.2023Fee for grant paid
01.02.2023Fee for publishing/printing paid
01.02.2023Receipt of the translation of the claim(s)
Divisional application(s)EP16206296.2  / EP3207931
Opposition(s)18.12.2023No opposition filed within time limit [2024/08]
Fees paidRenewal fee
09.06.2017Renewal fee patent year 03
25.06.2018Renewal fee patent year 04
12.06.2019Renewal fee patent year 05
23.06.2020Renewal fee patent year 06
10.06.2021Renewal fee patent year 07
09.06.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ15.03.2023
DK15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
IE03.06.2023
LU03.06.2023
NO15.06.2023
GR16.06.2023
BE30.06.2023
CH30.06.2023
IS15.07.2023
PT17.07.2023
[2024/24]
Former [2024/21]CZ15.03.2023
DK15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
IE03.06.2023
LU03.06.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2024/15]CZ15.03.2023
DK15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
LU03.06.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2024/10]CZ15.03.2023
DK15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2024/09]CZ15.03.2023
DK15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2023/50]CZ15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2023/49]CZ15.03.2023
EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
PT17.07.2023
Former [2023/48]EE15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RS15.03.2023
SE15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
PT17.07.2023
Former [2023/46]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RS15.03.2023
SE15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
PT17.07.2023
Former [2023/38]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RS15.03.2023
SE15.03.2023
NO15.06.2023
GR16.06.2023
Former [2023/37]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
RS15.03.2023
SE15.03.2023
NO15.06.2023
GR16.06.2023
Former [2023/36]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
RS15.03.2023
SE15.03.2023
NO15.06.2023
Former [2023/35]HR15.03.2023
LT15.03.2023
RS15.03.2023
NO15.06.2023
Former [2023/34]LT15.03.2023
RS15.03.2023
Former [2023/33]LT15.03.2023
Documents cited:Search[E]WO2015095576  (SIGNPATH PHARMA INC [US]) [E] 1,2,4-6,8-15 * page 3, line 30 - page 4, line 36 * * page 4, line 22 - line 35 * * page 5, line 27 - page 6, line 2 * * page 30, line 19 - line 22 * * page 45, line 17 - line 30 * * claims 1-25 ** claims 4-6,11-12,23-25 *
International search[A]WO2007062028  (TAP PHARMACEUTICAL PROD INC [US]) [A] 1-27 * See abstract; claims 1, 9. *;
 [A]US2010120890  (FEDIDA DAVID [CA], et al) [A] 1-27 * See abstract; claims 84-98. *;
 [XA]WO2012167212  (SIGNPATH PHARMA INC [US], et al) [X] 1-2, 5-8, 10, 22-27 * See abstract; page 4, lines 3-14; claims 12-15, 17, 20. * [A] 3-4, 9, 11-21;
 [X]  - WANG, JINGXIONG et al., "Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether-a-go-go-related gene (HERG) K+ channel function", Circulation, (20010000), vol. 104, no. 22, pages 2645 - 2648, XP055242000 [X] 1-2, 5-8, 10, 22-24 , 26-27 * See abstract; page 2647. *

DOI:   http://dx.doi.org/10.1161/hc4701.100513
 [A]  - RAJAMANI, S. et al., "Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine", British journal of pharmacology, (20060000), vol. 149, no. 5, pages 481 - 489, XP055242001 [A] 1-27 * See the whole document. *

DOI:   http://dx.doi.org/10.1038/sj.bjp.0706892
by applicantUS2007048284
 US2008255464
 US2010004549
 US2010120890
 WO2012167212
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.